| Subject: | FDA Issues Safety Communication About Erythropoiesis-Stimulating Agents (ESAs) |
| Category: | Food and Drug Administration (FDA)
|
| Published: | Wed, 17 Feb 2010 - 11:00 am |
| The Food and Drug Administration (FDA) is requiring all Erythropoiesis-Stimulating Agents (ESAs) to be prescribed and used under a risk management program, known as a risk evaluation and mitigation strategy (REMS), to ensure the safe use of these drugs. The ESAs are marketed under the names Epogen, Procrit, and Aranesp. The FDA required Amgen, the manufacturer of these products, to develop a risk management program because studies show that ESAs can increase the risk of tumor growth and shorten... The full article is available to StayAlert subscribers. Click here for a free trial subscription. |
|
RESOURCES:
External Links:
|
|
StayAlert! notifies healthcare customers of all federal and regulatory body legislation changes impacting the healthcare industry, including TJC (JCAHO), CDC, CMS, DHHS, FDA, OSHA, OIG and many others. StayAlert! complements this with regulatory implementation action plans. StayAlert! serves as a virtual healthcare department, augmenting traditional employee staffed departments and freeing employees to perform other vital functions. StayAlert! is the only comprehensive clinical and regulatory service providing organizations in the healthcare arena with practical applications to meet complex mandated federal requirements. |
|
